Search

Your search keyword '"McLaughlin, Peter"' showing total 71 results

Search Constraints

Start Over You searched for: Author "McLaughlin, Peter" Remove constraint Author: "McLaughlin, Peter" Publisher wiley Remove constraint Publisher: wiley
71 results on '"McLaughlin, Peter"'

Search Results

3. Application Theme 2 – Groundwater Evaluations

4. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

5. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

6. Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy

7. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

8. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model

9. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity

10. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

11. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

12. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas

13. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

14. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

15. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

16. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas

19. Marginal zone lymphomas

20. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

21. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

22. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

23. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

26. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma

28. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

32. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

33. Thalidomide for patients with recurrent lymphoma

36. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy

38. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

39. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

42. Gamow u. Stannard.: The New World of Mr. Tompkins/Porter.: Physicists in Conflict/Hertz.: Die Constitution der Materie. Eine Vorlesung über die Grundlagen der Physik aus dem Jahre 1884/Guicciardini.: Reading the Principia. The Debate on Newton's Mathemati

43. Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma

46. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial

50. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis

Catalog

Books, media, physical & digital resources